ABUS vs AMZN · P/E 5.4, rev $180.1M vs P/E 31, rev $716.92B
Arbutus Biopharma Corp (ABUS) versus Amazon.com Inc (AMZN) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Amazon.com Inc (AMZN) is a internet retail company listed on NASDAQ. It is led by Andrew R. Jassy.
Latest reported ABUS revenue for 2026-06-30 was $180.1M. Net income was $164.6M. Revenue was up 0.6% from 2026-03-31 to 2026-06-30. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported AMZN revenue for 2025-12-31 was $716.92B. Net income was $77.67B. Revenue was up 12.4% from 2024-12-31 to 2025-12-31. AMZN currently screens at market cap $2.55T and trailing P/E 30.6.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. AMZN currently screens at market cap $2.55T and trailing P/E 30.6.
Not investment advice. Open the ABUS and AMZN stock pages for the full models.
Not investment advice.